Figure 2.
Time to progression. (A) All patients. (B) Those patients who were untreated or had received treatment before their therapy with fludarabine and rituximab. ○ represents patients who had not progressed at last follow-up.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.